Clinical and genomic characterization of patients diagnosed with the acute myeloid leukemia (AML) with BCR‐ABL1, a Swedish registry‐based study

Philadelphia-positive or (t9;22)(q34;q11)/BCR/ABL1 AML is a rare entity, often difficult and sometimes clinically indistinguishable from the myeloid blast crisis of Chronic Myeloid Leukemia (CML). It is generally regarded as high risk AML, because the results with chemotherapy were poor and the only treatment, which could improve the survival, is the allogeneic stem cell transplantation. The objective of the project is to describe the long-term outcome of the patients with Philadelphia-positive AML who underwent allogeneic stem cell transplantation or received other therapy, based on the Swedish Acute Leukemia registry and European Group for Blood and Marrow Transplantation (EBMT) registry.